“A biotech ETF coming to market in the midst of a global pandemic could prove to be a case of good timing for multiple reasons,” observes the author of today’s article in regards to the newest biotech exchange-traded fund on the scene – one that focuses on the under-served but high-growth-potential small-cap segment. For more on this new fund, what makes it a compelling option for risk-tolerant investors, and how it’s likely to be affected by an evolving coronavirus vaccine timeline, CLICK HERE.